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Abstract—This study investigated the contribution of estrogen receptors (ERs)  and  for epicardial coronary artery
function, vascular NO bioactivity, and superoxide (O2
) formation. Porcine coronary rings were suspended in organ
chambers and precontracted with prostaglandin F2 to determine direct effects of the selective ER agonists
4,4,4-(4-propyl-[
1H]pyrazole-1,3,5-triyl)tris-phenol (PPT) or 2,3-bis(4-hydroxyphenyl)-propionitrile (DPN) or the
nonselective ER agonist 17-estradiol. Indirect effects on contractility to U46619 and relaxation to bradykinin were
assessed and effects on NO, nitrite, and O2
 formation were measured in cultured cells. Within 5 minutes, selective ER
activation by PPT, but not 17-estradiol or the ER agonist DPN, caused rapid, NO-dependent, and endothelium-
dependent relaxation (495%; P0.001 versus ethanol). PPT also caused sustained endothelium- and NO-independent
vasodilation similar to 17-estradiol after 60 minutes (723%; P0.001 versus ethanol). DPN induced endothelium-
dependent NO-independent relaxation via endothelium-dependent hyperpolarization (404%; P0.01 versus ethanol).
17-Estradiol and PPT, but not DPN, attenuated the responses to U46619 and bradykinin. All of the ER agonists
increased NO and nitrite formation in vascular endothelial but not smooth muscle cells and attenuated vascular smooth
muscle cell O2
 formation (P0.001). ER activation had the most potent effects on both nitrite formation and
inhibiting O2
 (P0.05). These data demonstrate novel and differential mechanisms by which ER and ER activation
control coronary artery vasoreactivity in males and females and regulate vascular NO and O2
 formation. The findings
indicate that coronary vascular effects of sex hormones differ with regard to affinity to ER and ER, which will
contribute to beneficial and adverse effects of hormone replacement therapy. (Hypertension. 2007;49:1364-1370.)
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V
ascular effects of estrogens (reviewed in References 1
and 2) can be divided in acute (nongenomic) and
chronic (genomic) effects. 17-Estradiol and selective estro-
gen receptor (ER) modulators directly induce relaxation in
different vascular beds; however, whether vasodilatory ef-
fects occur dependent or independent of the endothelium
remains controversial.3 Moreover, the natural estrogen 17-
estradiol may indirectly affect both vascular tone and vaso-
reactivity to different contractile or relaxant agonists, includ-
ing U46619 or bradykinin.4–6Endothelium-dependent effects
of 17-estradiol involve endothelial factors, including effects
on reactive oxygen species, NO, and superoxide anion (O2
).1
Two distinct subtypes of ERs have been cloned, ER7 and
ER.8 Both are located intracellularly and on the cell mem-
brane9,10 and are present in vascular smooth muscle11 and
endothelial cells.12 Nongenomic vascular effects of 17-
estradiol on endothelial cells are thought to be mediated by
plasma membrane–bound and caveolar ERs, involving acti-
vation of protein kinases and endothelial NO synthase.13
17-Estradiol and other estrogenic compounds, including
those found in conjugated equine estrogens used for hormone
replacement therapy,14 bind to ERs.7,8 The contribution of
ER and ER to regulation of vascular tone in the coronary
circulation is still obscure and only recently have suitable
pharmacological tools become available, including 4,4,4-(4-
propyl-[
1H]pyrazole-1,3,5-triyl)tris-phenol (PPT), a selective
ER receptor agonist, and 2,3-bis(4-hydroxyphenyl)-
propionitrile (DPN), a selective agonist for ER.15–18
Both male gender and estrogen deficiency after menopause
are independent cardiovascular risk factors (reviewed in
References 1 and 2). The incidence of coronary artery disease
is low in premenopausal women14,19 but increases after
menopause and with aging,20 indicating protective effects of
endogenous estrogens on the cardiovascular system. Impor-
tantly, the administration of exogenous nonhuman hormones,
such as conjugated equine estrogens and methoxyprogestero-
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1364neacetate in postmenopausal women, increases clinical com-
plications, such as thrombosis in veins and coronary arter-
ies.14,21 In humans, atherosclerosis typically develops in large
conduit arteries, such as the epicardial coronaries. Porcine
coronary arteries are widely used as a suitable experimental
model of human coronary arteries because of the high
anatomic and physiological similarities.22 Therefore, using
selective agonists for both ERs as well as the nonselective ER
agonist 17-estradiol, the objective of the present study was
to investigate whether and through which mechanisms com-
bined or selective activation of ER and ER affects epicar-
dial coronary artery tone, vascular reactive oxygen species,
and bioactivity.
Methods
Tissue Preparations
Experiments were in accordance with the institutional guidelines and
the Guide for the Care and Use of Laboratory Animals, published by
the National Institutes of Health. Porcine hearts of either sex were
obtained from a local abattoir and immediately immersed in cold
physiological Krebs–Ringer bicarbonate solution (in millimoles per
liter): 118.6 NaCl, 4.7 KCl, 2.5 CaCl2, 1.2 MgSO4, 25.1 NaHCO3,
1.2 KH2PO4, 0.026 Na2Ca-EDTA, and 10.1 glucose. The left anterior
descending coronary artery was dissected free from surrounding
myocardium, cleaned of adherent fat and connective tissue, and cut
into rings 4 to 5 mm in length. Six rings were prepared from each
coronary artery. In a subset of rings, the endothelium was removed
by gently rubbing the intimal surface with a wooden probe.
Vascular Function Experiments
Vascular rings were mounted onto stainless steel hooks and placed in
organ chambers containing Krebs–Ringer solution (25 mL [pH 7.4],
37°C, 95% O2, and 5% CO2) as described.23 Rings were progres-
sively stretched until optimal tension for generating force during
isometric contraction was reached (4.0 g) and repeatedly exposed to
KCl (60 mmol/L; iso-osmotically replaced) to determine a maximal
contraction. Before the experiments, all rings were preincubated with
the nonselective cyclooxygenase-inhibitor meclofenamate
(1 mol/L) for 30 minutes. A subset of rings was additionally
incubated with N
G-nitro-L-arginine methyl ester (L-NAME;
300 mol/L) for 30 minutes to inhibit endothelial NO synthesis.
The integrity of vascular smooth muscle was determined by
precontracting with acetylcholine (1 mol/L), and the absence or
presence of the endothelium was determined by the relaxant response
to bradykinin (0.1 nmol/L to 1 mol/L; data not shown); endothe-
lium-independent relaxation was determined using sodium nitroprus-
side (300 mol/L; data not shown). In rings precontracted with
prostaglandin F2, direct vascular effects of 17-estradiol, PPT, or
DPN (10 mol/L each)16–18 were recorded for 60 minutes. Ethanol
at a final concentration of 0.2% (vol/vol) served as solvent control.
A subset of rings exposed to DPN was preincubated with inhibitors
of endothelium-dependent hyperpolarization factors, charybdotoxin
in combination with apamin (0.1 mol/L each).24 After repeated
washings, rings were incubated again with 17-estradiol, PPT, or
DPN (10 mol/L) and precontracted with U46619 (1 nmol/L to
0.3 mol/L). Endothelium-dependent relaxation was determined
using bradykinin (0.01 nmol/L to 1 mol/L), and endothelium-
independent relaxation was determined using sodium nitroprusside.
Cell Culture Experiments
Human umbilical vein endothelial cells (HUVECs) were isolated by
collagen digestion and cultured in endothelial cell growth medium
(PromoCell). HUVEC-derived EA.hy 926 endothelial cells (a kind
gift of Dr C J Edgell, University of North Carolina at Chapel Hill,
Chapell Hill, NC)25 were grown as described.26
Human vascular smooth muscle cells (VSMC) were isolated using
the explant technique and cultured as described.27 Cells of passages
3 to 6 were used for all of the experiments.
Determination of Endothelial NO Synthesis
To determine the effects of ER agonists, NO release by HUVECs
was bioassayed using guanylyl cyclase–containing RFL-6 rat lung
fibroblasts as reporter cells.26 HUVECs were treated with ER
agonists (all 10 mol/L) for 5 minutes. Thereafter, NO-containing
conditioned media from the HUVECs were transferred to RFL-6
cells to stimulate guanylyl cyclase. The cGMP content of the RFL-6
samples was determined by radioimmunoassay.26
In additional experiments, HUVECs, EA.hy 926 cells, or VSMCs
were treated with ER agonists for 60 minutes, and nitrite accumu-
lation in the cell culture supernatant was measured as an indicator of
NO production by chemiluminescence using an NOA 280 nitric
oxide analyzer (Sievers) or by the Griess reaction according to the
instructions of the manufacturer (Caymann). Total protein content
was determined (Bradford), and nitrite levels were normalized for
protein.26 The nitrite concentration in control cells was set 100%.
Vascular O2
 Formation
Subconfluent VSMCs were starved for 24 hours and exposed to
17-estradiol, PPT, DPN (all 10 mol/L), or ethanol for 30 minutes.
Three independent experiments were performed, with measurements
being performed in triplicate. Cells were suspended in Krebs-HEPES
buffer, and O2
 generation was monitored using a chemilumines-
cence probe (L-012; 500 mol/L, Wako Chemicals) in a luminom-
eter (Lumat LB 9507) as described previously.28
Drugs
Acetylcholine chloride, apamin, bradykinin, charybdotoxin, 17-
estradiol, L-NAME, prostaglandin F2, sodium nitroprusside dihy-
drate, and U46619 were from Sigma-Aldrich. DPN and PPT were
from Tocris (Anawa). DPN, PPT, and 17-estradiol were dissolved
in 100% ethanol. All of the other substances were dissolved in water;
stock solutions were diluted in Krebs solution to the required final
concentration before use.
Calculations and Statistical Analysis
Data are expressed as meanSEM, and n equals the number of
animals. Contraction was expressed as the percentage of contraction
to KCl 60 mmol/L, and relaxation was expressed as the percentage
of precontraction. EC50 values (as negative logarithm: pD2), area
under the curve, and maximal responses were calculated by nonlin-
ear regression analysis.29 One-way ANOVA, ANOVA for repeated
measurements (followed by Bonferroni–Dunn posthoc test), or
unpaired Student’s t test was used when appropriate. A P0.05 was
considered significant.
Results
Selective ER Activation Induces Rapid
Endothelium- and NO-Dependent Relaxation
The selective ER agonist PPT induced a rapid relaxation
(495% within 5 minutes; P0.001 versus ethanol [ETOH])
that was not seen with either 17-estradiol or the selective
ER agonist DPN (Figure 1, original tracings, and Figure
2A). As shown in Figure 3A, the rapid response induced by
PPT was abolished in rings without endothelium (51%
versus 495%; P0.001 versus PPT) or after pretreatment
with the NO synthase inhibitor L-NAME (61% versus
495%; P0.001 versus PPT). Data for males and females
are presented separately in Table 1.
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Are Endothelium- and NO-Independent
After 60 minutes of recording time, relaxation caused by PPT
was increased further and became comparable to 17-
estradiol (723%; P0.001 versus ETOH), whereas DPN
induced a smaller but significant response (404%; P0.01
versus ETOH; Figure 1, original tracings and Figure 2B).
Data for males and females are presented separately in Table
1. Denudation or inhibition of NO synthesis did not affect
relaxation to PPT measured after 60 minutes (673% and
632%, respectively; P value not significant versus PPT).
17-Estradiol induced a time-dependent relaxation (774%
after 60 minutes; P0.001 versus ETOH; Figure 1, original
tracing and Figure 2B). Inhibition of NO synthesis with
L-NAME did not affect this response (Figure 3C). Calculated
values for area under the curve and maximal response are
given in Table 2.
Sustained Relaxation Following ER Activation
Involves Endothelium-Dependent Hyperpolarization
The sustained response of DPN recorded after 60 minutes
was unaffected by L-NAME (334% versus 404%; P value
not significant; Figure 3B) and comparable to solvent control
after removal of the endothelium (242% versus 404%;
P0.01 versus DPN alone). After pretreatment with
L-NAME, charybdotoxin, and apamin, relaxation was com-
pletely inhibited (172% versus 333%; P0.01 versus
L-NAME alone). Calculated values for area under the curve
and maximal response are given in Table 2.
Thromboxane-Mediated Contraction
Is ER-Sensitive
Contractions to the thromboxane receptor agonist U46619
were attenuated in rings pretreated with either the unselective
agonist 17-estradiol or the ER-selective agonist PPT
(P0.05 and P0.001 versus ETOH; Figure 4A), whereas
DPN had no effect. Maximal relaxations and sensitivity of
endothelium-dependent relaxations to bradykinin were re-
duced after PPT and 17-estradiol in rings precontracted with
U46619 (P0.05 versus ETOH; Figure 4B and Tables 3 and
4). Pretreatment with DPN had no effect.
Effects of ER Agonists on NO Synthesis in Human
Vascular Cells
Incubation with PPT, DPN, or 17-estradiol (10 mol/L
each) increased NO production in HUVECs (cGMP genera-
tion in RFL-6 reporter cells) after 5 minutes of treatment
(P0.05 versus ETOH; Figure 5A). Nitrite concentration
also significantly increased after treatment with PPT, DPN, or
17-estradiol after 60 minutes (P0.05 versus ETOH), the
Figure 1. Original recordings of acute and sustained relaxant
responses of ER agonists in epicardial coronary arteries. 17-
Estradiol (E2), PPT, and DPN induced a sustained time-dependent
relaxant effect in precontracted arteries (10 mol/L; original experi-
ments recorded for 60 minutes) compared with solvent-control
ETOH. Only activation of ER by PPT showed a rapid dilator com-
ponent within 1 minute that was completely inhibited by NO inhi-
bition (L-NAME) or endothelial denudation. Arrows indicate admin-
istration of increasing concentrations of prostaglandin F2 (PGF2),
ER agonists, or sodium nitroprusside (SNP).
Figure 2. Maximal relaxant effects of ER ago-
nists in epicardial coronary arteries after 5 min-
utes (A) and 60 minutes (B). The ER agonist
PPT induced potent relaxation after 5 minutes,
whereas after 60 minutes, relaxations caused
by PPT and 17-estradiol were comparable. In
contrast, the response to DPN was signiﬁcantly
less. Data are meanSEM; n8 to 20. *P0.01
vs ETOH; †P0.01 vs PPT.
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PPT (P0.05 versus DPN and 17-estradiol; Figure 5B). In
HUVEC-derived EA.hy 926 hybridoma cells, nitrite synthe-
sis after 60 minutes was increased only by 17-estradiol
(14720%; P0.05 versus ETOH). In contrast, PPT, DPN,
and 17-estradiol did not induce nitrite formation in VSMCs
(data not shown).
Inhibition of Smooth Muscle Cell O2
 Formation
by ER Agonists
Treatment of VSMCs with 17-estradiol or DPN reduced
O2
 generation by 395% and 382%, respectively
(P0.001 versus ETOH). Interestingly, the ER-selective
agonist PPT had a much stronger inhibitory effect on
O2
 generation than the other agonists (620.5%; P0.001
versus ETOH and P0.01 versus DPN).
Discussion
This study demonstrates that, in epicardial porcine coronary
arteries of males and females, selective activation of ER by
PPT involves a rapid, NO-dependent component, as well as
sustained relaxant response, whereas selective ER activation
causes sustained relaxation only. The sustained relaxing
effect of combined ER activation by 17-estradiol was
similar to that of PPT; however, 17-estradiol lacked rapid
dilator effects. Rapid relaxation after ER activation was
NO-dependent, whereas sustained responses after activation
of ER or both ERs were not. Activation of ER, but not of
ER, also reduced thromboxane A2-receptor–mediated vaso-
constriction. Finally, differential effects of selective ER
agonists on endothelial NO bioactivity and on VSMC O2

formation were observed.
This study is the first to demonstrate that, in epicardial
coronary arteries, the dilator response after selective ER
activation involves 2 independent components. On the one
hand, rapid, endothelium- and NO-dependent vasodilation
occurs within the first minutes, which is followed by a
sustained endothelium-independent dilator component reach-
ing a maximum after 1 hour similar to that of the unselec-
tive ER agonist 17-estradiol. Importantly, 17-estradiol,
which also activates ER,3 lacked the rapid NO-dependent
dilator response, suggesting a possible inhibitory effect of
ER on ER-mediated NO-dependent activity. Endothelium-
and NO-dependent relaxant effects have been demonstrated
TABLE 1. Maximal Effects of Acute Relaxant Responses to ER
Agonists in Porcine Coronary Arteries
Exposure Time Agonist Males Females
5 min
ETOH 111 1
PPT 555* 438*
DPN 31† 72*†
E2 162*† 205*
60 min
ETOH 2742 1 3
PPT 735* 703*
DPN 363† 437*†
E2 766* 786*
Data are presented separately for arteries of male and female pigs. Data are
meanSEM, n4–10. E2 indicates 17-estradiol.
*P0.05 vs ETOH; †P0.05 vs PPT and E2 (for each time point).
TABLE 2. Acute Relaxant Effects of ER Agonists in Porcine
Coronary Arteries
Agonist and Treatment AUC Emax
ETOH 4052 3 3
PPT 1797* 662*
PPTL-NAME 1107*† 612*
PPT denuded 1156*† 653*
DPN 816* 382*
DPNL-NAME 5392 9 4
DPN denuded 5232 4 2
DPNL-NAMECHAP 71† 142†
E2 18013* 744*
E2L-NAME 17715* 734*
Area under the curve (AUC) and maximal responses (Emax) were calculated by
nonlinear regression analysis. Data are meanSEM, n8t o2 0 .
*P0.05 vs ETOH; †P0.05 vs agonist alone.
Figure 3. Acute relaxant effects of ER agonists PPT (A), DPN (B), and 17-estradiol ([E2] C) in epicardial coronary arteries. Selective
ER activation using PPT induced a rapid relaxation not noted with either 17-estradiol or ER-agonist DPN; the rapid response was
inhibited by L-NAME or denudation. DPN-induced relaxation was inhibited by endothelial denudation or inhibition of endothelium-
dependent hyperpolarization (CHAP). LN indicates L-NAME; E-, denuded; CHAP, charybdotoxinapamin. Data are meanSEM; n8t o
20. *P0.01 vs ETOH; †P0.05 vs agonist alone.
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17-estradiol,31–35 yet none of these previous studies reported
a rapid or NO-dependent dilator component to PPT, even at
concentrations higher than those used in the present
study.17,30 It has been shown previously that NO is released
after short-term treatment with 17-estradiol from
HUVECs.12 Although there is evidence that NO release from
endothelial cells is mediated by ER,36,37 more recent data
suggest that both ER and ER can activate endothelial NO
synthase and mitogen-activated protein kinases.38 In line with
these observations, we show here that selective activation of
either ER increases bioactive NO in HUVECs and also
rapidly stimulates endothelial cell cGMP formation. It is
noteworthy that again the strongest effect was seen after
selective activation of ER. Increased cGMP after 17-
estradiol was also detected in HUVEC-derived EA.hy 926
hybridoma cells,25 which, unlike in HUVECs,38 express only
a truncated form of ER.39 Thus, either selective or unselec-
tive activation of ERs appears to stimulate endothelial cell
NO formation of most species. In the present study, the rapid
NO-mediated dilator response in porcine coronary arteries
was only seen after selective activation ER, suggesting
possible species differences in ER expression and/or function.
Increased NO bioactivity may also be affected by antioxidant
effects of estrogen agonists because of their phenolic struc-
ture.40 Our experiments using human VSMCs show that all of
the ER agonists used inhibit vascular O2
 generation. Because
the most potent effect was again seen with the ER agonist
PPT, it appears reasonable to speculate that scavenging of
O2
 by PPT also indirectly contributes to the observed NO
bioavailability and the rapid vasodilator component observed
in the present study.
The maximum effect of the sustained vasodilator response
to the ER agonist PPT was equally potent but somewhat
delayed compared with that induced by 17-estradiol. In
contrast, the maximum response to the ER agonist DPN was
less pronounced. This is in agreement with a study using
aortic rings of female rats, in which the ER agonist PPT
acutely and concentration-dependently induced relaxations
similar to those by 17-estradiol,15 whereas the ER agonist
DPN had no effect.15 We found that the sustained dilator
component to all 3 of the ER agonists was NO independent,
which is in line with earlier studies using 17-estradiol in
coronary arteries of humans,41,42 dogs,43 or adult pigs of
either sex.44,45 Therefore, the sustained dilator response must
involve mechanisms distinct from NO, possibly inhibition of
VSMC Ca
2 influx.3
We surprisingly found that selective ER-mediated epicar-
dial coronary vasodilation was in part endothelium-
dependent. Because combined cyclooxygenase and NO inhi-
bition had no effect on the endothelium-dependent portion of
the relaxant response to DPN, the results suggested a role for
other vasodilator mechanisms, such as endothelium-mediated
hyperpolarization. Indeed, experiments using inhibitors of
endothelium-dependent hyperpolarization showed an attenu-
ation of the relaxant responses after ER activation, confirm-
ing this hypothesis. This mechanism may be particularly
relevant to epicardial coronary arteries, which are known to
produce high levels of endothelium-dependent hyperpolar-
izing factor,46 and to conditions when NO bioactivity is low,
such as atherosclerosis or aging.
TABLE 3. Acute Effects of ER Agonists on Contractions to
U46619 in Porcine Coronary Arteries
Vasoconstrictor Agonist pD2 AUC Emax
U46619 ETOH 8.30.1* 5246 7 4
PPT 8.20.0* 222† 312*†
DPN 8.20.0* 4526 7 3
E2 7.90.0 243† 515
EC50 values (as negative logarithm: pD2), area under the curve (AUC), and
maximal responses (Emax) were calculated by nonlinear regression analysis.
Data are meanSEM, n8t o1 8 .
*P0.05 vs 17-estradiol (E2); †P0.05 vs ETOH and DPN.
TABLE 4. Acute Effects of ER Agonists on Relaxant Responses
to Bradykinin in Porcine Coronary Arteries
Vasodilator Agonist pD2 AUC Emax
Bradykinin ETOH 7.80.1 28011 980
PPT 7.30.1* 21813* 931*†
DPN 7.40.0 23749 6 0
E2 7.10.1*† 1989*† 941*
EC50 values (as negative logarithm: pD2), area under the curve (AUC), and
maximal responses (Emax) were calculated by nonlinear regression analysis.
Data are meanSEM, n7 to 16. E2 indicates 17-estradiol.
*P0.05 vs ETOH; †P0.05 vs DPN.
Figure 4. Acute effects of ER agonists on con-
tractions to the thromboxane A2 receptor ago-
nist U46619 and bradykinin in epicardial coro-
nary arteries. 17-Estradiol and PPT attenuated
the contractile and relaxant response, whereas
DPN had no effect. Data are meanSEM; n8
to 18. *P0.05 vs ETOH; †P0.05 vs ETOH for
PPT and 17-estradiol (E2).
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affect vasoreactivity to contracting and relaxing substances.
The vasoconstrictor thromboxane A2 is released in high
concentrations from aggregating platelets at sites of coronary
plaque rupture and is a key event in the pathogenesis of acute
coronary syndromes. We found that contractions to the
thromboxane A2 receptor agonist U46619 were markedly
attenuated after ER activation only but unaffected by ER
activation, indicating another indirect and NO-independent
vasodilator function of ER. The effect of unselective ER
activation in response to 17-estradiol was less pronounced
than that of selective ER activation and comparable to
previous studies.5 This suggests that (1) activation of ER
alone is sufficient and (2) that ER possibly regulates
vascular ER function. Indeed, our results suggest that ER
activation appears to attenuate the ER-mediated effects
during combined ER activation with 17-estradiol, which
would be compatible with a functional cross-talk between
both ERs. Whether selective ER agonists also affect function
of vasoconstrictors such as endothelin-1 in epicardial coro-
nary arteries47,48 remains to be determined in future studies.
Perspectives
The observed NO-dependent coronary dilator response and
attenuation of O2
 anion formation after selective ER
activation may have therapeutic implications for human
vascular disease, including acute coronary syndromes and
restenosis,30,49,50 and possibly also for hormone therapy in
postmenopausal women.14,15 Our results also show that the
effects of ER activation were similar in coronary arteries from
male and female pigs. Finally, because endogenous 17-
estradiol also contributes to vascular homeostasis in
males,51,52 effects of endogenous estrogens on the epicardial
coronary arterial circulation, a vascular bed that is highly
susceptible to atherosclerosis in humans,20 may be possibly
also of similar relevance for vascular disease in men and
women.
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